A consortium led by CardiacBooster in partnership with FIRE1 and Integer Holdings was awarded €9.3 million in DTIF funding to develop CardiacBooster’s unique mechanical cardiac support technology into a comprehensive medical device platform for the treatment of cardiogenic shock. The consortium aims to bring significant innovation in an indication where mortality rates have remained too...
Physicians use mechanical ventricular assist devices to support patients through periods of hemodynamic instability. Ventricular assist devices used for short-term support are usually brought into the patient through minimally invasive methods, mostly by accessing blood vessels in the groin (percutaneous delivery). In particular, these catheter-based devices are used in cardiogenic shock patients and patients undergoing...
Percutaneous coronary procedures allow the minimally invasive treatment of coronary artery disease. These procedures are a mainstay of interventional cardiology and usually uneventful. However, some procedures carry an elevated risk either due to the physiological or anatomical condition of the patient, or the complexity of a particular procedure, and are deemed high-risk procedures (high-risk PCI)....
Cardiogenic shock is a medical emergency characterized by the inability of the heart to pump sufficient blood volume for adequate organ and tissue perfusion. Cardiogenic shock carries a dire prognosis with a high in-hospital mortality. Ventricular assist devices are used to support the heart in cardiogenic shock patients, with the aim of unloading the heart...
